MRT-Untersuchungen bei axialer und peripherer Spondyloarthritis

Baraliakos, Xenofon; Braun, J.

doi:10.1007/s00393-011-0894-3

Cited by 9 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 2 This has allowed physicians to diagnose axSpA earlier, and thus offers the possibility to initiate early treatment for better symptom relief, aiming for the prevention of structural damage or halting of structural progression. 3 …”

Section: Introductionmentioning

confidence: 99%

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis

et al. 2017

View full text Add to dashboard Cite

ObjectiveTo report MRI outcomes and explore the relationship between clinical remission and MRI inflammation in patients with axial spondyloarthritis (axSpA) from the RAPID-axSpA trial, including radiographic (r-)axSpA and non-radiographic (nr-)axSpA.MethodsRAPID-axSpA (NCT01087762) was double-blind and placebo-controlled to week 24, dose-blind to week 48 and open-label to week 204. Patients were randomised to certolizumab pegol (CZP) or placebo. Placebo patients entering dose-blind were rerandomised to CZP. MRIs performed at baseline, weeks 12, 48 and 96 were scored by 2 reviewers independently: Spondyloarthritis Research Consortium of Canada (SPARCC) for sacroiliac (SI) joints; Berlin modification of the Ankylosing Spondylitis spine MRI scoring system for disease activity (Berlin) for spine. Inflammation thresholds: SPARCC≥2; Berlin>2. Remission thresholds: SPARCC<2 (SI joints); Berlin≤2 (spine); Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (<1.3, clinical).ResultsAcross 163 patients in the MRI set (109 CZP; 54 placebo), week 12 mean changes from baseline in MRI scores were greater for CZP versus placebo: SPARCC: −4.8 (SD 8.6) vs −1.6 (7.8; p<0.001); Berlin: −2.9 (4.2) vs 0.2 (4.8; p<0.001). Improvements were maintained to week 96. Week 12 MRI remission was achieved by 52.6% of patients with baseline MRI inflammation in SI joints, 62.0% in the spine and 37.9% of patients with both. MRI remission rates were sustained to week 96, with similar trends in r-axSpA and nr-axSpA. At week 96, 57.5% vs 65.9% of patients achieving versus not achieving clinical remission had MRI remission.ConclusionsCZP reduced inflammation in the spine and SI joints in patients with r-axSpA and nr-axSpA, with improvements maintained over 96 weeks. Substantial proportions of patients achieved MRI remission. Concordance between clinical remission and current definitions of absence of MRI inflammation was limited.Trial registration numberNCT01087762; Post-results.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Herausfordernd gestaltet sich das Monitoring der objektiven entzündlichen Aktivität, da das CRP trotz inflammatorischer Aktivität negativ sein kann. Mittels MRT der Wirbelsäule kann ein Knochenmarködem als Ausdruck der entzündlichen Aktivität objektiviert werden [71].…”

Section: Voraussetzungen Zur üBerweisung Von Imid-patienten Zum Dermaunclassified

Interdisziplinäres Management immunmediierter Erkrankungen – eine österreichische Perspektive

Högenauer

Häusler

Pieringer

et al. 2019

J. Gastroenterol. Hepatol. Erkr.

View full text Add to dashboard Cite

ZusammenfassungImmunmediierte inflammatorische Erkrankungen (IMID) sind eine klinisch heterogene Gruppe von Erkrankungen, die genetische, ätiologische und auch klinische Überschneidungen aufweisen. Nach dem heutigen Stand der Forschung liegen den sog. primären IMID gemeinsame pathogene Mechanismen und zytokinassoziierte Signaltransduktionswege zugrunde. Zu den primären IMID zählen unter anderem chronisch-entzündliche Darm‑, Haut- und Augenerkrankungen sowie rheumatische Erkrankungen. Patienten, die an einer primären IMID erkrankt sind, weisen ein erhöhtes Risiko für die Entwicklung einer sekundären IMID auf. Die vorliegende Arbeit skizziert die Abgrenzung zwischen primären und sekundären IMID unter Berücksichtigung von Komplikationen und Komorbiditäten. Ausgehend von den Fächern Gastroenterologie, Dermatologie, Rheumatologie und Ophthalmologie wird ein möglicher optimaler interdisziplinärer Umgang mit IMID-Patienten diskutiert. Im speziellen werden Leitsymptome, die auf eine IMID hinweisen, und diagnostische Maßnahmen beschrieben, die vor Überweisung eines Patienten zum entsprechenden Spezialisten durchgeführt werden sollten. Da einzelne Patienten, die unter mehreren IMID leiden, eine therapeutische Herausforderung darstellen, können hierfür interdisziplinäre Sprechstunden bzw. sog. Immunoboards in der klinischen Praxis hilfreich sein.

show abstract

“…MRI can detect early sacroiliitis symptoms such as subchondral bone marrow edema. MRI is a crucial diagnostic tool in managing spondyloarthritis (SpA) as it can detect active and chronic changes before structural changes occur, with the ability to show active lesions and structural changes [ 10 ]. Imaging is crucial in evaluating patients with inflammatory back pain in SpA, as it helps in early detection and appropriate treatment to prevent irreversible changes [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

ASNET: A Novel AI Framework for Accurate Ankylosing Spondylitis Diagnosis from MRI

Tas,

Kaya,

Macin

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Background: Ankylosing spondylitis (AS) is a chronic, painful, progressive disease usually seen in the spine. Traditional diagnostic methods have limitations in detecting the early stages of AS. The early diagnosis of AS can improve patients’ quality of life. This study aims to diagnose AS with a pre-trained hybrid model using magnetic resonance imaging (MRI). Materials and Methods: In this research, we collected a new MRI dataset comprising three cases. Furthermore, we introduced a novel deep feature engineering model. Within this model, we utilized three renowned pretrained convolutional neural networks (CNNs): DenseNet201, ResNet50, and ShuffleNet. Through these pretrained CNNs, deep features were generated using the transfer learning approach. For each pretrained network, two feature vectors were generated from an MRI. Three feature selectors were employed during the feature selection phase, amplifying the number of features from 6 to 18 (calculated as 6 × 3). The k-nearest neighbors (kNN) classifier was utilized in the classification phase to determine classification results. During the information phase, the iterative majority voting (IMV) algorithm was applied to secure voted results, and our model selected the output with the highest classification accuracy. In this manner, we have introduced a self-organized deep feature engineering model. Results: We have applied the presented model to the collected dataset. The proposed method yielded 99.80%, 99.60%, 100%, and 99.80% results for accuracy, recall, precision, and F1-score for the collected axial images dataset. The collected coronal image dataset yielded 99.45%, 99.20%, 99.70%, and 99.45% results for accuracy, recall, precision, and F1-score, respectively. As for contrast-enhanced images, accuracy of 95.62%, recall of 80.72%, precision of 94.24%, and an F1-score of 86.96% were attained. Conclusions: Based on the results, the proposed method for classifying AS disease has demonstrated successful outcomes using MRI. The model has been tested on three cases, and its consistently high classification performance across all cases underscores the model’s general robustness. Furthermore, the ability to diagnose AS disease using only axial images, without the need for contrast-enhanced MRI, represents a significant advancement in both healthcare and economic terms.

show abstract

MRT-Untersuchungen bei axialer und peripherer Spondyloarthritis

Cited by 9 publications

References 41 publications

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis

Interdisziplinäres Management immunmediierter Erkrankungen – eine österreichische Perspektive

ASNET: A Novel AI Framework for Accurate Ankylosing Spondylitis Diagnosis from MRI

Contact Info

Product

Resources

About